TalpheraTLPH
TLPH
About: Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
Employees: 13
0
Funds holding %
of 7,312 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
29% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 7
28% more capital invested
Capital invested by funds: $2.14M [Q4 2024] → $2.74M (+$599K) [Q1 2025]
8.49% more ownership
Funds ownership: 23.95% [Q4 2024] → 32.44% (+8.49%) [Q1 2025]
9% less funds holding
Funds holding: 35 [Q4 2024] → 32 (-3) [Q1 2025]
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
Research analyst outlook
We haven’t received any recent analyst ratings for TLPH.
Financial journalist opinion
Neutral
Seeking Alpha
1 month ago
Talphera, Inc. (TLPH) Q1 2025 Earnings Call Transcript
Talphera, Inc. (NASDAQ:TLPH ) Q1 2025 Earnings Conference Call May 14, 2025 4:30 PM ET Company Participants Raffi Asadorian - Chief Financial Officer Vincent Angotti - Chief Executive Officer Shakil Aslam - Chief Medical Officer Conference Call Participants Operator Welcome to the Talphera First Quarter 2025 Financial Results Conference Call. This call is being webcast live via the Events page of the Investors section of Talphera's website at www.talphera.com.
Neutral
PRNewsWire
1 month ago
Talphera Announces First Quarter 2025 Financial Results and Provides Corporate Update
Cash and investments at March 31, 2025, as adjusted to include the proceeds from the first tranche of the private placement financing which closed on April 2, 2025, were $9.8 million Three new clinical study sites activated and screening patients thus far in 2025, with five additional sites expected by mid-year, for a total of 13 Conference call and webcast to be held Wednesday, May 14, 2025 at 4:30 pm ET SAN MATEO, Calif. , May 14, 2025 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced first quarter 2025 financial results and provided a corporate update.
Neutral
PRNewsWire
2 months ago
Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 14, 2025
SAN MATEO, Calif. , May 7, 2025 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release first quarter 2025 financial results after market close on Wednesday, May 14, 2025, then host a live webcast and conference call at 4:30 p.m.
Positive
Zacks Investment Research
2 months ago
All You Need to Know About Talphera (TLPH) Rating Upgrade to Strong Buy
Talphera (TLPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Positive
Zacks Investment Research
3 months ago
Talphera (TLPH) Upgraded to Buy: What Does It Mean for the Stock?
Talphera (TLPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Neutral
Seeking Alpha
3 months ago
Talphera, Inc. (TLPH) Q4 2024 Earnings Call Transcript
Talphera, Inc. (NASDAQ:TLPH ) Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ET Company Participants Raffi Asadorian - CFO Vincent Angotti - CEO Shakil Aslam - CMO Conference Call Participants Thomas Yip - H.C. Wainwright Naz Rahman - Maxim Group Operator Welcome to the Talphera Fourth Quarter and Full Year 2024 Financial Results Conference call.
Neutral
PRNewsWire
3 months ago
Talphera Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
The U.S. Food and Drug Administration (FDA) agreed to reduce the number of patients in the NEPHRO CRRT study from 166 to 70 Talphera expects the registrational NEPHRO CRRT study to be completed by the end of 2025 Cash and investments at December 31, 2024 of $8.9 million, together with the private placement financing recently announced of up to $14.8 million, expected to provide capital through target completion of the NEPHRO study in the fourth quarter of 2025 Conference call and webcast to be held Monday, March 31, 2025 at 4:30 pm ET SAN MATEO, Calif. , March 31, 2025 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced fourth quarter and full year 2024 financial results and provided a corporate update.
Neutral
PRNewsWire
3 months ago
Talphera Announces Agreement with the FDA to Reduce the NEPHRO CRRT Study Size to 70 Patients From 166 and a Private Placement Financing Priced At-the Market of up to $14.8 Million
The U.S. Food and Drug Administration (FDA) agreed to reduce the number of patients in the NEPHRO CRRT study from 166 to 70 patients, of which 6 patients are already enrolled Talphera believes the NEPHRO CRRT study should be completed by the end of 2025 Existing investors, Nantahala Capital and Rosalind Advisors led the capital commitment priced at-the-market as defined by Nasdaq rules $4.925 million in gross proceeds at first closing with the potential to receive an additional $9.85 million across two $4.925 million tranches upon achieving certain patient enrollment milestones Cash and investments at December 31, 2024 of $8.9 million, together with the expected proceeds from the financing of up to $14.8 million should provide capital through targeted completion of the NEPHRO CRRT study by the end of 2025 SAN MATEO, Calif. , March 31, 2025 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), (Talphera), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced its agreement with the FDA to reduce the size of the NEPHRO CRRT study to 70 patients from the 166 previously included in the study protocol.
Neutral
PRNewsWire
3 months ago
Talphera to Host Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update Call and Webcast on Monday, March 31, 2025
SAN MATEO, Calif., March 26, 2025 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release fourth quarter and full-year 2024 financial results after market close on Monday, March 31, 2025, then host a live webcast and conference call at 4:30 p.m.
Neutral
PRNewsWire
5 months ago
Talphera Announces Agreement with the FDA for Prior Approval Supplement Review to Reduce the Number of Patients in the NEPHRO CRRT Study
Submission of a Prior Approval Supplement for a reduction in the number of patients in the NEPHRO CRRT study is expected within the coming week The FDA agreed to two additional protocol changes expected to accelerate enrollment in the NEPHRO CRRT study SAN MATEO, Calif. , Jan. 14, 2025 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that following a meeting with the U.S. Food and Drug Administration (FDA), the agency has agreed to review a Prior Approval Supplement (PAS) requesting a reduction in the number of patients in the NEPHRO CRRT clinical study.
Charts implemented using Lightweight Charts™